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Objective: Immune complexes (ICs) trigger humoral immune responses. Therefore, the 29 
identification of constituent antigens within ICs would have very different clinical 30 
significance than identification of free antigens. 31 
Design and Methods: Here, we applied immune complexome analysis of serum to the study 32 
of seven major autoimmune diseases—anti-neutrophil cytoplasmic antibody-associated 33 
vasculitis, Takayasu’s arteritis, mixed connective tissue disease, dermatomyositis, Sjögren’s 34 
syndrome, systemic scleroderma, and systemic lupus erythematosus— and healthy donors to 35 
comprehensively identify antigens incorporated into circulating ICs and to find 36 
disease-specific antigens. 37 
Results: We identified 468 distinct IC- associated antigens using this method.  Importantly, 38 
62 of those antigens were disease-specific antigens, and there were at least three 39 
disease-specific antigens for each of the seven autoimmune diseases.  Of the disease-specific 40 
antigens identified, coiled-coil domain-containing protein 158 and spectrin were identified as 41 
potential autoantigens important to SSc and SS pathogenesis, respectively; notable titin and 42 
spectrin autoantibodies are reportedly found in SSc and SS patients, respectively. 43 
Conclusion: Immune complexome analysis may be generally applicable to the study of the 44 





   For a long time, immune complexes (ICs) assembly was thought to represent a common 48 
pathogenic pathway for several diseases (infections, vasculitis, and connective tissue 49 
autoimmune disorders).  Actually, concentrations of circulating ICs (CICs) in sera from 50 
patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), or systemic 51 
scleroderma (SSc) were significantly higher than those in sera from healthy controls [1, 2].  52 
Many researchers have investigated the mechanisms by which ICs could underlie 53 
pathogenicity [3].  An autoimmune response is directed against several autoantigens [4, 5]; 54 
therefore, comprehensive profiling of the autoantigens that actually assemble into ICs may 55 
provide insight into the pathophysiology of specific autoimmune diseases, and such profiling 56 
could form the basis for novel diagnosis and treatment strategies for these diseases.  57 
However, such comprehensive profiling studies for CICs are limited because tools screening 58 
of ICs are lacking. 59 
We developed a proteomic strategy, designated immune complexome analysis, in which 60 
ICs are separated from whole serum and then subjected to direct tryptic digestion and 61 
nano-liquid chromatography-tandem mass spectrometry (nano-LC-MS/MS) to 62 
comprehensively identify and profile constituent antigens in CICs [6].  We used this method 63 
to identify CIC-associated antigens in sera from patients with RA, and found that 64 
thrombospondin-1 is a constituent of CICs and is more highly specific and sensitive for 65 
established and early RA than other conventional diagnostic markers such as rheumatoid 66 
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factor or anti-citrulline-containing protein/peptide antibody [6, 7]. 67 
   In this report, we used immune complexome analysis of serum to study seven major 68 
autoimmune diseases—anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), 69 
Takayasu’s arteritis (TA), mixed connective tissue disease (MCTD), dermatomyositis (DM), 70 
Sjögren’s syndrome (SS), SSc, and SLE—to comprehensively identify antigens incorporated 71 
into CICs and find disease-specific antigens. 72 
 73 
Materials and methods 74 
Serum samples were collected from 66 patients; each patient had AAV (n=7; 35-86 years; 75 
3 female; 4 patients are Microscopic polyantitis and 3 patients are Granulomatosis with 76 
polyantitis), TA (n=7; 28-63 years; 7 female), MCTD (n=9; 43-77 years; 9 female), DM (n=8; 77 
30-69 years; 6 female), SS (n=14; 35-78 years; 14 female), SSc (n=7; 55-78 years; 6 female), 78 
or  SLE (n=14; 16-67 years; 13 female) as diagnosed based on classification criteria from the 79 
Ministry of Health, Labour and Welfare, Japan for AAV, MCTD, and DM; classification 80 
criteria from the American College of Rheumatology for TA, SSc, and SLE; or the criteria for 81 
SS proposed by the American-European Consensus Group. All sample collection and 82 
diagnoses were performed at Nagasaki University Hospital and all the patients were newly 83 
diagnosed.  Also, healthy donors (n=11; 30-65 years; 2 female) are enrolled in this study.  84 
Each serum sample was subjected to a single pretreatment process and replicate 85 
nano-LC-MS/MS analyses.  All experiments were performed in accordance with the 86 
Helsinki Declaration and with approval from the institutional ethics committees of the 87 
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Graduate School of Biomedical Sciences, Nagasaki University.  Each patient provided 88 
written informed consent for their participation in this study. 89 
CICs were purified by magnetic beads with immobilized Protein G or Protein A 90 
(PureProteome®, Millipore, Darmstadt, Germany).  The tryptic digestion procedure and 91 
nano-LC-MS/MS analysis were performed as previously [6]. 92 
 93 
Results and discussion 94 
   Here, we present the first comprehensive identification of the constituent antigens 95 
assembled into CICs from patients with AAV, TA, MCTD, DM, SS, SSc, or SLE (Table S1).  96 
We identified 341 and 264 human antigens via immune complexome analysis with Protein G 97 
or Protein A beads, respectively; 468 distinct antigens were identified in all, and each of these 98 
was found in independent samples from two or more patients (Table S2).  Notably, only 29% 99 
(137) of these 468 distinct antigens were recovered with both Protein G and Protein A beads; 100 
204 antigens were recovered only when using Protein G beads, and 127 antigens were 101 
recovered only when using Protein A beads.  This indicates that the parallel use of Protein G 102 
and Protein A beads recovered a wider range of antigens than the use of either bead type alone.  103 
Furthermore, among 341 and 264 antigens identified with Protein G or Protein A, 127 and 92 104 
antigens were also found in healthy donors, respectively; therefore, these antigens were 105 
thought to form common CICs in human bodies (Table S2).  It is interesting that much more 106 
antigens identified with Protein G than Protein A and there is a little overlap between Protein 107 
G and Protein A immune complexome.  The association constant between IgG and Protein G 108 
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was reported to be 4-times higher than that between IgG and Protein A [8].  It is known that 109 
IgG3 is captured on Protein G (but not Protein A) and IgM, IgA, IgD and IgE are captured on 110 
Protein A (but not Protein G).  High association constant and binding to IgG3 of Protein G 111 
and distinct affinity of Protein A to IgM, IgA, IgD and IgE may contribute to more antigens 112 
identified with Protein G than Protein A and a little overlap between Protein G and Protein A. 113 
Of the 468 distinct antigens identified, 62 were detected in only one disease group and not 114 
in any other disease groups by using Protein G or Protein A (Table 1).  Also, these antigens 115 
were not found in healthy donors.  Although there is the possibility that a protein 116 
nonspecifically binds to Protein G or Protein A beads, those disease-specific antigens are not 117 
thought to directly bind to the beads because nonspecifically binding proteins should be found 118 
in multiple diseases.  Also, in this study, many disease-specific antigens are identified; 119 
therefore, it is difficult to determine if each protein nonspecifically binds to the beads by 120 
using a recombinant or natural protein as our previous study [6]. 121 
In this study, relatively many disease-specific antigens were found in SSc and SS.  122 
Namely, 9 disease-specific antigens were associated with SSc even though only seven SSc 123 
patients were enrolled in this study; moreover, SS was associated with 2-fold more 124 
disease-specific antigens than was SLE, even though the number of patients with SS was 125 
equal to that with SLE.  Reportedly, concentrations of CICs are elevated in patients with SSc 126 
or SS [9, 10]; thus, these elevated CIC concentrations may contribute to the large number of 127 
distinct types of disease-specific antigens associated with each disease.  Only 6 128 
disease-specific antigens associated with AAV, TA, MCTD, or DM were detected with Protein 129 
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G beads; however, 19 of the disease-specific antigens associated with AAV, TA, MCTD, or 130 
DM were detected with Protein A beads.  This finding may indicate that there were more 131 
CICs associated with IgA, IgD, IgE, or IgM than those associated with IgG.  Conversely, 132 
more of the disease-specific antigens associated with SS, SSc, or SLE were recovered only 133 
with Protein G beads. 134 
To our knowledge, most of the 62 disease-specific antigens have never been reported to be 135 
associated with the respective autoimmune disease; however, some do have a recognized 136 
association with the respective disease.  Some of the autoantibodies previously reported to 137 
be associated with SS are known to recognize proteins that contain one or more coiled-coil 138 
domains.  SS is known to produce autoantibodies that react with a 52-kDa protein 139 
component of the SS-A antigen.  The antigenic region of this 52 kDa protein is recognized 140 
by all SS-A antibody-positive sera and contains a sequence motif reminiscent of a leucine 141 
zipper that is predicted to form a coiled-coil region [11].  Similarly, we specifically detected 142 
coiled-coil domain-containing protein 158 in SS sera.  Spectrin was specifically detected 143 
with Protein A beads in serum from patients with SS.  Spectrin is a protein that was first 144 
characterized in human erythrocytes; the nonerythrocyte spectrin is called fodrin [12].  145 
Studies have suggested that 1) the α-subunit of fodrin is cleaved during apoptosis, 2) fodrin 146 
plays a role in the development of SS, and 3) fodrin is a candidate autoantigen in primary SS 147 
[13, 14].  Although some of our results were consistent with these previous reports, our 148 
method did not detect the autoantigens targeted by well-known autoantibodies (e.g. SS-A, 149 
SS-B, Jo-1, Scl-70 antibodies) that are associated with SS, DM, SSc, or some combination 150 
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thereof.  Therefore, it is possible that these autoantibodies do not form ICs with their 151 
corresponding autoantigens and immune complexome analysis may specifically identify those 152 
antigens that actually assemble into ICs. 153 
The sensitivity of each disease specific antigens was less than 33%.  The sensitivity of 154 
individual disease-specific antigens may be improved by developing ELISA methods that ea 155 
ch detects a certain IC with high specificity [15]; if such ELISAs were developed, these 156 
disease-specific antigens may become promising diagnostic or pathogenic biomarkers. 157 
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IPI00926948.1 Uncharacterized protein 3/1             
IPI00217511.1 Seven transmembrane helix receptor 2/1             
IPI00555948.1 
Androgen-regulated short-chain dehydrogenase/reductase 1 variant 
(Fragment) 
    2/1         
IPI01012262.1 Uncharacterized protein     2/1         
IPI00910896.1 cDNA FLJ56556, highly similar to Alpha-1-syntrophin       2/1       
IPI00982295.1 Uncharacterized protein       2/1       
IPI00023711.2 Envoplakin         2/1     
IPI00103630.3 Isoform 2 of Protein phosphatase 1E         3/1     
IPI00249982.4 Isoform 1 of Death-inducer obliterator 1         2/1-9     
IPI00643437.1 Uncharacterized protein         3/1     
IPI00784980.1 Isoform 1 of Coiled-coil domain-containing protein 158         2/1-3     
IPI00796214.1 
Isoform 2 of Mediator of RNA polymerase II transcription subunit 
12-like protein 
        2/1     
IPI00796249.1 Uncharacterized protein         4/1     
IPI00796316.5 Uncharacterized protein         7/1-3     
IPI00829812.3 13 kDa protein         2/1     
1 
 
IPI00844250.2 cDNA FLJ52101         2/1     
IPI00853581.1 Uncharacterized protein         3/1-2     
IPI00917789.1 Uncharacterized protein         2/2     
IPI00979799.1 Similar to VH-7 family (N54P3)D/J protein         2/2     
IPI00968154.1 Uncharacterized protein           2/1   
IPI00946590.1 26 kDa protein           2/1   
IPI00447173.1 Antigen MLAA-39           2/1   
IPI00973260.1 
cDNA FLJ55558, highly similar to Regulating synaptic membrane 
exocytosis protein 1 
          2/1   
IPI01009738.1 Isoform 3 of Golgin subfamily A member 4           2/1   
IPI00436634.4 Isoform 3 of Nipped-B-like protein           2/1   
IPI00006900.1 Something about silencing protein 10           2/1   
IPI00304557.2 
Short palate, lung and nasal epithelium carcinoma-associated 
protein 2 
            3/1 
IPI00827548.3 
cDNA FLJ44825 fis, clone BRACE3046609, highly similar to 
Homo sapiens inhibitor of Bruton agammaglobulinemia tyrosine 
kinase (IBTK), mRNA 
            2/1 
IPI00868939.1 Similar to Sarcoma antigen NY-SAR-41             2/1 
IPI00908840.1 Isoform 3 of AT-rich interactive domain-containing protein 5B             2/1 
IPI00945093.1 Protein             2/1 
IPI01011877.1 
cDNA FLJ59435, highly similar to Homo sapiens outer dense fiber 
of sperm tails 2 (ODF2), transcript variant 2, mRNA 









































IPI00552578.2 Serum amyloid A protein 2/1             
IPI00973428.1 Putative uncharacterized protein 2/3             
IPI01025129.1 12 kDa protein 2/1             
IPI00007138.2 Isoform 2 of Disks large-associated protein 4 2/1             
IPI00885166.2 polyadenylate-binding protein 4-like   2/1           
IPI00032931.2 Isoform 2 of Peroxisomal targeting signal 1 receptor   2/1           
IPI00965543.1 collagen alpha-1(XI) chain isoform C preproprotein   2/1           
IPI00827532.1 Anti-folate binding protein (Fragment)     3/1         
IPI00217511.1 Seven transmembrane helix receptor     2/1         
IPI00973424.1 Putative uncharacterized protein     2/3-4         
IPI00645207.2 Uncharacterized protein     2/1         
IPI00917650.2 Protein PIEZO1     2/1         
IPI00432678.1 MRSS6228     2/1         
IPI00977998.1 Uncharacterized protein     2/1         
IPI00007193.7 Isoform 2 of Ankyrin repeat domain-containing protein 26       2/1       
IPI00968154.1 Uncharacterized protein       2/1       
IPI00552943.3 V1-11 protein       2/1       
IPI00470871.6 Uncharacterized protein       2/1       
IPI00023466.2 Protein AF-17       2/1       
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IPI00423464.1 Putative uncharacterized protein DKFZp686K03196         5/13-15     
IPI00896471.2 Isoform 2 of Protein SZT2         2/1     
IPI00973032.1 V1-17 protein         2/2     
IPI00022987.3 PRO0483         2/1     
IPI00736625.2 Uncharacterized protein C3orf43         2/1     
IPI00333015.7 Isoform 2 of Spectrin beta chain, brain 1         2/1     
IPI00922213.2 
cDNA FLJ53292, highly similar to Homo sapiens fibronectin 1 
(FN1), transcript variant 5, mRNA 
          2/1-9   
IPI00970895.1 Isoform 2 of PR domain-containing protein 11           2/1   
IPI01026317.1 cDNA FLJ55146, highly similar to Complement C4-B             2/1 
IPI00165579.6 Isoform 2 of Cytosolic non-specific dipeptidase             2/1 
IPI00924585.1 neurabin-1 isoform 5             2/1 
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